Floatz logo

Onabotulinum Toxin A

Reversible Cerebral Vasoconstriction Syndrome

University of AlbertaPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Reversible Cerebral Vasoconstriction Syndrome cohort.

Asset / SponsorPhaseRating
VERAPAMIL SLOW RELEASE
Johns Hopkins University
Phase 4BB
Nimodipine
Johns Hopkins University
Phase 4BB

Same molecule, other indications

Onabotulinum Toxin A is also rated in:

migraine disorderDormant
BB
Indicative ·
66 / 100
View asset →
neuralgiaDormant
CCC
Indicative ·
53 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →